Why Visionflex Group (ASX:VFX) is leaning on subscription revenue and NSW Health hardware orders after a smaller FY26 loss

Sonal Goyal

16 October 2026 11:02 PM AEDT

Why Visionflex Group (ASX:VFX) is leaning on subscription revenue and NSW Health hardware orders after a smaller FY26 loss

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

FY26 Revenue fell 10 per cent to $4.19 million, while subscription and support revenue rose 27 per cent to $1.72 million.
The statutory loss before tax fell 84 per cent to $0.60 million, including a $1.63 million non-cash Fair Value gain on the conversion of convertible notes.
Cash was $1.62 million at 30 June 2026, and borrowings fell to $0.58 million from $2.47 million after $3.25 million of notes converted to equity.

Visionflex Group (ASX:VFX) sells hardware and software for remote clinical examinations, and its FY26 results, released on 28 August 2026, show a Business attempting to move from one-off hardware sales towards recurring subscription revenue. The statutory loss fell sharply, but part of the improvement came from a non-cash accounting gain and lower costs, while total revenue declined. All figures are in Australian dollars.

What Visionflex does

The company supplies telehealth devices, such as examination cameras, together with the software and support that remote clinicians rely on. Named customers include NSW Health, Amplar Health, which is part of Medibank (ASX:MPL), the Royal Flying Doctor Service in South Australia and the Northern Territory, and BlueCare Queensland.

The FY26 numbers

Revenue for the year to 30 June 2026 was $4.19 million, down 10 per cent from $4.65 million. Hardware revenue fell 17 per cent to $2.30 million, which management attributed to customers deferring deliveries into FY27 rather than to lost demand. Subscription and support revenue rose 27 per cent to $1.72 million, lifting Recurring Revenue to 41 per cent of the total from 29 per cent. Annual recurring revenue was $1.9 million, up 3 per cent, and gross Margin improved to 86 per cent from 78 per cent.

The statutory loss before tax fell 84 per cent to $0.60 million. That figure includes a $1.63 million non-cash fair value gain arising from the conversion of convertible notes into Equity in November 2025. Excluding that gain, the underlying EBITDA loss was $1.63 million, an improvement of 34 per cent.

Cash and funding

Net operating cash outflow improved 60 per cent to $1.26 million, and the company said Operating Cash Flow was positive in the second half, a first for the group. It also received a Research and Development tax Credit of $0.57 million. Set against the nine-month operating outflow of about $2.0 million reported in April, the full-year figure implies, on simple arithmetic, a positive fourth quarter.

Cash at 30 June 2026 was $1.62 million. Borrowings fell to $0.58 million from $2.47 million after $3.25 million of convertible notes converted to equity, and net liabilities narrowed to $15,000 from $1.82 million. The company has a $0.6 million R&D funding facility, established in April 2026, of which $0.4 million has been drawn, as well as a Debt Facility with cornerstone investor Adcock Private Equity, from which $75,000 was repaid in July 2026. Any future equity raising would dilute existing shareholders.

Contracts versus revenue

Contract values quoted by the company are total contract values rather than recognised revenue. NSW Health awarded a contract worth about $0.8 million on 26 June 2026 for 127 general examination cameras and 162 video examination camera glass kits; the announcement did not specify revenue timing, although the results indicate delivery took place in the fourth quarter. The Amplar Health contract is worth about $0.6 million and the Royal Flying Doctor Service contract about $0.3 million. In April the company cautioned that subscription churn pressure would remain elevated.

Sector and risks

Healthcare procurement cycles are long and hardware orders tend to be lumpy, as the FY26 deferral illustrates. Risks include concentration among government and large health-service customers, reliance on a cornerstone lender, and the small scale of recurring revenue relative to costs.

What to Watch

Rather than numeric targets, the company has set out FY27 priorities that include growing recurring revenue and scaling its unattended-access capability, with a Royal Flying Doctor Service rollout beginning in the first quarter of FY27. Director nominations closed on 8 October 2026, and the Annual General Meeting is scheduled for 19 November 2026.

FAQs

Q:What does Visionflex Group sell?

A:Visionflex supplies telehealth devices such as examination cameras, together with software and support used by remote clinicians, to customers including NSW Health and the Royal Flying Doctor Service.

Q:Why did Visionflex's FY26 loss fall so sharply?

A:The statutory loss before tax fell 84 per cent to $0.60 million, helped by a $1.63 million non-cash fair value gain from converting convertible notes into equity and by lower costs; the underlying EBITDA loss was $1.63 million.

Q:When is Visionflex's annual general meeting?

A:The annual general meeting is scheduled for 19 November 2026, after director nominations closed on 8 October 2026.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.